New kidney scan measure could sharpen blockage detection

NCT ID NCT07811388

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers at Assiut University are comparing a newer kidney scan measure called Normalized Residual Activity (NORA) with standard measures from 99mTc-DTPA diuretic renography. The study enrolls 57 children and adults referred for suspected urinary tract obstruction. All participants receive the standard scan with a radioactive tracer and a diuretic. The goal is to see whether NORA better distinguishes true blockage from non-obstructive widening of the urinary tract.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
99mTc-DTPA, a radioactive tracer used in kidney imaging, plus furosemide, a diuretic
What this could lead to
If NORA proves more accurate, doctors could rely on it to tell true kidney blockage from harmless widening, helping patients avoid unnecessary surgery or get needed treatment sooner.
What could go wrong
This is a small single-center study of 57 people, so its findings may not hold up in larger or more varied groups. The reference standard itself depends on surgery or long follow-up, which can be imperfect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 57 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric or adult patients referred for 99mTc-DTPA diuretic renography because of suspected urinary tract obstruction.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients fulfilling all of the following criteria will be eligible for inclusion: 1. Pediatric or adult patients referred for 99mTc-DTPA diuretic renography because of suspected urinary tract obstruction. 2. Availability of a clinical reference standard (e.g., confirmation of obstruction via surgical findings/pyeloplasty, or proven non-obstruction via stable long-term clinical and radiological follow-up of at least 6-12 months). Exclusion Criteria: Patients meeting any of the following criteria will be excluded: 1. Patients with severe renal impairment. 2. Patients with renal congenital anomalies e.g. horseshoe kidneys 3. Technical failure during the scan, including severe patient motion artifacts or failure to properly administer the diuretic

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary tract obstruction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.